136 related articles for article (PubMed ID: 37921226)
1. A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease.
Salhotra A; Falk L; Park G; Sandhu K; Ali H; Modi B; Hui S; Nakamura R
Expert Rev Clin Immunol; 2024 Feb; 20(2):169-184. PubMed ID: 37921226
[TBL] [Abstract][Full Text] [Related]
2. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
3. Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease.
Donato V; Kim HT; Stowe P; Reynolds CG; Ritz J; Koreth J; Whangbo JS
Front Immunol; 2022; 13():954966. PubMed ID: 36189229
[TBL] [Abstract][Full Text] [Related]
4. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
Asano T; Meguri Y; Yoshioka T; Kishi Y; Iwamoto M; Nakamura M; Sando Y; Yagita H; Koreth J; Kim HT; Alyea EP; Armand P; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Maeda Y; Tanimoto M; Ritz J; Matsuoka KI
Blood; 2017 Apr; 129(15):2186-2197. PubMed ID: 28151427
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.
Koreth J; Kim HT; Jones KT; Lange PB; Reynolds CG; Chammas MJ; Dusenbury K; Whangbo J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Chen YB; Avigan D; Blazar BR; Antin JH; Ritz J; Soiffer RJ
Blood; 2016 Jul; 128(1):130-7. PubMed ID: 27073224
[TBL] [Abstract][Full Text] [Related]
6. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
Matsuoka K; Koreth J; Kim HT; Bascug G; McDonough S; Kawano Y; Murase K; Cutler C; Ho VT; Alyea EP; Armand P; Blazar BR; Antin JH; Soiffer RJ; Ritz J
Sci Transl Med; 2013 Apr; 5(179):179ra43. PubMed ID: 23552371
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.
Belizaire R; Kim HT; Poryanda SJ; Mirkovic NV; Hipolito E; Savage WJ; Reynolds CG; Fields MJ; Whangbo J; Kubo T; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Blazar BR; Antin JH; Ritz J; Soiffer RJ; Koreth J
Blood Adv; 2019 Apr; 3(7):969-979. PubMed ID: 30936057
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.
Whangbo JS; Nikiforow S; Kim HT; Wahl J; Reynolds CG; Rai SC; Kim S; Burden A; Alho AC; Lacerda JF; Alyea EP; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J; Koreth J
Blood Adv; 2022 Nov; 6(21):5786-5796. PubMed ID: 35475885
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner.
McDonald-Hyman C; Flynn R; Panoskaltsis-Mortari A; Peterson N; MacDonald KP; Hill GR; Luznik L; Serody JS; Murphy WJ; Maillard I; Munn DH; Turka LA; Koreth J; Cutler CS; Soiffer RJ; Antin JH; Ritz J; Blazar BR
Blood; 2016 Aug; 128(7):1013-7. PubMed ID: 27385791
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells.
Kim N; Jeon YW; Nam YS; Lim JY; Im KI; Lee ES; Cho SG
Cytokine; 2016 Feb; 78():22-6. PubMed ID: 26624506
[TBL] [Abstract][Full Text] [Related]
11. A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease.
Salhotra A; Sandhu K; O'Hearn J; Ali H; Nakamura R; Modi BG
Expert Rev Clin Immunol; 2023 Mar; 19(3):241-251. PubMed ID: 36440483
[TBL] [Abstract][Full Text] [Related]
12. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
Chen X; Wang Y; Huang X; Geng S; Li C; Zeng L; Huang L; Du X; Weng J; Lai P
Int Immunopharmacol; 2023 Apr; 117():109746. PubMed ID: 36827923
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Trial of Extracorporeal Photopheresis for Chronic Graft-versus-Host Disease Reveals Significant Disease Response and No Association with Frequency of Regulatory T Cells.
Gandelman JS; Song DJ; Chen H; Engelhardt BG; Chen YB; Clark WB; Giver CR; Waller EK; Jung DK; Jagasia M
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2373-2380. PubMed ID: 29981848
[TBL] [Abstract][Full Text] [Related]
14. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.
Whangbo JS; Kim HT; Mirkovic N; Leonard L; Poryanda S; Silverstein S; Kim S; Reynolds CG; Rai SC; Verrill K; Lee MA; Margossian S; Duncan C; Lehmann L; Huang J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Blazar BR; Antin JH; Soiffer RJ; Ritz J; Koreth J
Blood Adv; 2019 Sep; 3(17):2550-2561. PubMed ID: 31471324
[TBL] [Abstract][Full Text] [Related]
15. Propensity Score Matching Analysis Comparing the Efficacy and Steroid Tapering Benefit of Extracorporeal Photopheresis to Best Available Therapy in Third-Line or Beyond Treatment for Chronic GvHD.
Novitzky-Basso I; Patriquin C; Linn SM; Chiarello C; Pasic I; Lam W; Law A; Michelis FV; Gerbitz A; Viswabandya A; Lipton J; Kumar R; Mattsson J; Barth D; Kim DDH
Transplant Cell Ther; 2023 Dec; 29(12):773.e1-773.e10. PubMed ID: 37797719
[TBL] [Abstract][Full Text] [Related]
16. Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
Spałek A; Grygoruk-Wiśniowska I; Gruenpeter K; Panz-Klapuch M; Helbig G
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556924
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on oral chronic graft-versus-host disease from immunobiology to morbid diagnoses.
Tollemar V; Garming Legert K; Sugars RV
Front Immunol; 2023; 14():1151493. PubMed ID: 37449200
[TBL] [Abstract][Full Text] [Related]
18. Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease.
Oarbeascoa G; Lozano ML; Guerra LM; Amunarriz C; Saavedra CA; Garcia-Gala JM; Viejo A; Revilla N; Acosta Fleitas C; Arroyo JL; Martinez Revuelta E; Galego A; Hernandez-Maraver D; Kwon M; Diez-Martin JL; Pascual C;
Biol Blood Marrow Transplant; 2020 Apr; 26(4):651-658. PubMed ID: 31917270
[TBL] [Abstract][Full Text] [Related]
19. Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Nursing Care.
Cazeau N; Rodriguez S
Clin J Oncol Nurs; 2023 May; 27(3):259-265. PubMed ID: 37267484
[TBL] [Abstract][Full Text] [Related]
20. Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation.
Meguri Y; Asano T; Yoshioka T; Iwamoto M; Ikegawa S; Sugiura H; Kishi Y; Nakamura M; Sando Y; Kondo T; Sumii Y; Maeda Y; Matsuoka KI
Front Immunol; 2022; 13():891925. PubMed ID: 35983059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]